In early drug development, waiting for critical information delays key decisions.
A formulation may appear promising, but the development team does not yet know whether it will remain stable long enough to support clinical use. Packaging may be selected before the product’s moisture sensitivity is fully understood. Manufacturing plans may move forward while questions remain about shelf life, storage conditions, or the effect of a formulation change.
These uncertainties affect more than the stability program. They influence formulation selection, packaging, manufacturing, regulatory strategy, clinical supply, and ultimately the timing of a first-in-human study.
By incorporating predictive stability assessment into the broader Molecule-to-Clinic program, FreeThink’s development team can make earlier decisions with greater scientific confidence.
The Limitations of a Sequential Development Process
Drug development is frequently divided among separate scientific functions. Analytical methods may be developed by one group, formulations evaluated by another, packaging selected elsewhere, and clinical supplies manufactured by a separate organization.
Each group may complete its assigned task successfully, but decisions made in one area can create delays or additional work in another.
For a small or early-stage development team, these delays are particularly consequential. Limited material, funding, and internal resources make it important to obtain useful information early and avoid unnecessary repetition of development work.
The challenge is not simply to perform each required activity faster. It is to connect analytical, formulation, packaging, manufacturing, regulatory, and clinical planning so that information from one area guides decisions in the others.
Integrating Predictive Stability into Drug Development
FreeThink Technologies’ Molecule-to-Clinic approach coordinates drug development from early API and drug-product work through clinical manufacturing, regulatory activities, and first-in-human studies.
One component of this approach is FreeThink’s accelerated stability process, embedded in its ASAPprime® software. Rather than waiting months or years for conventional long-term stability results, an ASAP study exposes a drug substance or drug product to scientifically selected combinations of temperature and relative humidity. The resulting degradation data are modeled to project performance under intended storage conditions.
ASAPprime® helps development teams evaluate:
- Likely shelf life
- Degradation behavior
- Moisture sensitivity
- Formulation alternatives
- Packaging requirements
- Storage conditions
- The potential effects of formulation, process, or material changes
The objective is not simply to produce a faster stability result. It is to generate information early enough to influence the development program.
Designing an Informative Stability Study
The usefulness of predictive stability begins with appropriate study design.
ASAPdesign™, a study-design function within ASAPprime®, helps establish the conditions, time points, and number of replicates needed to produce a statistically meaningful study. The design takes into account the stage of development to determine how precise mathematical models need to be at that point. For example, study designs are less extensive during early formulation work than when the ASAP study is used as primary data in market applications.
The goal is to generate degradation data across a scientifically useful range of conditions while making efficient use of available material and analytical resources.
This is particularly valuable during early development, when API or drug-product quantities may be limited and teams must balance the need for information against the amount of material available.
Once the study is completed, ASAPprime® analyzes the degradation response and determines isoconversion times under each condition, which is the time required for a product to reach a defined stability limit. These isoconversion times are then modeled to predict performance under long-term storage conditions.
Monte Carlo simulations are used to calculate the probability that the product will remain within its established specifications through the proposed shelf life.
This probabilistic approach provides a scientific basis for understanding uncertainty and assessing the level of confidence associated with a proposed shelf life.
Applying Predictive Stability to Formulation Development
At FreeThink, formulation development begins with a project-specific Target Product Profile (TPP). The TPP defines the product’s critical requirements and desired attributes, identifies gaps in the available data, and provides a scientific framework for selecting formulation technologies that best fit the product’s needs.
The formulation strategy may address solubility enhancement, controlled release, product stability, or a combination of these needs. Depending on the drug substance and intended product, FreeThink can evaluate approaches such as amorphous solid dispersions produced by spray drying or hot-melt extrusion, complexation, self-emulsifying systems, pH modification, particle-size reduction, matrix or multiparticulate extended-release systems, osmotic delivery, enteric protection, taste masking, and long-acting injectable depot systems.
Predictive stability is incorporated into this broader development process to help the team determine:
- Which realistic, complete formulations provide acceptable stability profiles
- Whether an excipient, process, or delivery technology changes a relevant degradation pathway
- Whether solubilization or controlled-release approaches introduce additional stability risks
- How moisture sensitivity and packaging requirements influence formulation selection
- Whether further optimization is needed before process development, scale-up, or technology transfer
For stable formulation development, FreeThink uses a tiered, material-sparing approach that tests realistic full formulations rather than relying on less predictive, binary 1:1 drug-excipient compatibility studies. This reduces the risk of excluding useful excipients based on conditions that do not represent the final dosage form and allows stability differences among viable formulations to be assessed earlier.
ASAPprime® strengthens this process by rapidly evaluating formulation viability and connecting degradation behavior with anticipated storage and packaging conditions. Once a formulation and process are defined, FreeThink supports intellectual property development and transfer the formulation technology and associated analytical methods to an appropriate manufacturer.
Connecting Formulation and Packaging Decisions
Packaging is sometimes selected late in development or based primarily on standard industry practices. However, the appropriate package depends on the specific sensitivity of the product.
FreeThink combines stability information about a product’s sensitivity to moisture and oxygen with packaging data. This allows FreeThink’s development team to evaluate how relative humidity and oxygen levels change inside a bottle, blister, or other package over time and how that change affects the drug product’s stability.
The analysis helps answer practical questions such as:
- Does the product require a high-barrier blister?
- Would a standard bottle provide adequate protection?
- Is a desiccant needed?
- Is an oxygen absorber an appropriate option?
- How could package size or product count affect stability?
- Could a less complex packaging configuration adequately support the intended shelf life?
Integrating packaging analysis with formulation and stability data reduces trial-and-error package selection and helps avoid both inadequate protection and unnecessary packaging complexity.
Supporting Clinical Supply and Regulatory Planning
Clinical development requires a drug product with a scientifically supported period of use. Waiting for extensive long-term stability data before making each decision can slow clinical manufacturing and study initiation. At the same time, assigning a shelf life without adequate support can introduce regulatory and supply risks.
The ASAP predictive stability assessment establishes a use period for clinical materials that is sufficient for US regulatory filings.
ASAP studies evaluate the impact of changes made during development, including changes to:
- Formulation composition
- Manufacturing process
- Raw-material source
- Packaging configuration
- Manufacturing scale
- Clinical presentation
By comparing stability behavior before and after a change, FreeThink’s development team provides scientific justification that the change does not affect shelf life without requiring additional long-term stability data.
FreeThink supports the preparation of regulatory documentation for clinical, marketing, and post-approval applications.
A More Connected Molecule-to-Clinic Strategy
Predictive stability provides its greatest value when it is not treated as an isolated laboratory exercise.
Within FreeThink’s integrated Molecule-to-Clinic program, stability findings inform analytical development, formulation selection, process development, packaging, clinical manufacturing, regulatory documentation, and clinical-supply planning.
This creates a connected decision process:
- Analytical methods establish how potency, purity, degradation, and performance will be measured.
- Formulation studies identify viable drug-product approaches.
- Predictive stability evaluates degradation risks and likely shelf life and informs stabilization strategies.
- Packaging analysis determines the level of environmental protection required.
- Manufacturing produces clinical materials based on the selected formulation and process.
- Regulatory and clinical teams use the resulting data to support the proposed development path.
A dedicated project management structure helps coordinate these activities and maintain communication among internal scientists, external providers, regulatory specialists, manufacturers, and clinical partners.
For early-stage companies, this coordination is as important as the individual technical services because it helps prevent critical dependencies from being overlooked.
Making Better Decisions Earlier
The purpose of accelerated development should not be to compress every activity without regard to scientific risk.
A more effective approach is to obtain the information needed for major decisions earlier in the program.
Predictive stability helps FreeThink:
- Compare formulations before committing to scale-up
- Identify degradation risks earlier and establish stabilization strategies as needed
- Select packaging based on measured product sensitivity
- Support an initial clinical shelf life
- Assess changes without automatically restarting the entire stability process
- Use limited development material efficiently
- Coordinate stability findings with manufacturing and regulatory plans
This allows speed to result from better scientific decisions rather than from simply performing conventional activities under greater time pressure.
Conclusion
The path from molecule to clinic depends on a series of connected technical and regulatory decisions. When analytical development, formulation, stability, packaging, manufacturing, and clinical planning are handled as separate activities, important information may arrive too late to guide the program effectively.
FreeThink’s Molecule-to-Clinic approach integrates these activities around a coordinated development strategy. ASAPprime® adds a distinctive capability by turning short-term, scientifically designed stability studies into predictions that inform formulation, packaging, shelf-life, regulatory, and clinical-supply decisions.
By understanding product stability earlier, development teams reduce uncertainty, focus resources on the strongest path forward, and advance toward clinical trials with greater confidence.
Contact FreeThink Technologies to discuss how predictive stability fits into your development program.
_______________________________________________________________________________________________________________
About FreeThink Technologies
FreeThink Technologies is a contract research organization specializing in accelerated drug development services. Our Molecule-to-Clinic platform integrates API development, preclinical development, clinical manufacturing, and regulatory strategy to help pharmaceutical companies advance drug candidates efficiently.
Founded in 2011, FreeThink’s Branford, Connecticut laboratories conduct experimental work to help companies develop formulations, establish analytical methods, and solve complex problems. FreeThink also develops and licenses ASAPprime®, the leading stability software package for determining shelf life under highly accelerated conditions.
Contact: info@freethinktech.com | +1 860 237 5800 | freethinktech.com
Services: API Development | Drug Development Services | Preclinical Development | Clinical Manufacturing | Pharmaceutical Research | GMP Manufacturing